Gilead’s CD47 trials freed of FDA hold—for the most part

Gilead's CD47 cancer program is back on track—for the most part—after the FDA lifted clinical holds placed in January on five trials.

But the agency is keeping two additional trials on ice, Gilead said Monday after market.